BACKGROUND Cholesterol is related to improvements in the rate of sustained virological response and a robust immune response against the hepatitis C virus(HCV).APOE gene polymorphisms regulate cholesterol levels modif...BACKGROUND Cholesterol is related to improvements in the rate of sustained virological response and a robust immune response against the hepatitis C virus(HCV).APOE gene polymorphisms regulate cholesterol levels modifying the course of the HCV infection.The relationship between cholesterol,APOE alleles,and the outcome of HCV infection has not been evaluated in the admixed population of Mexico.AIM To investigate the role of APOE-ε2,-ε3,and-ε4 alleles and the metabolic profile in the outcome of HCV infection.METHODS A total of 299 treatment-na?ve HCV patients were included in this retrospective study.Patients were stratified in chronic hepatitis C(CHC)(n=206)and spontaneous clearance(SC)(n=93).A clinical record was registered.Biochemical tests were assessed by dry chemistry assay.APOE genotypes were determined using a Real-Time polymerase chain reaction assay.RESULTS Total cholesterol,low-density lipoprotein cholesterol(LDL-c),triglycerides,and hypercholesterolemia were higher in SC than CHC patients as well as the frequency of the APOEε4 allele(12.4%vs 7.3%).SC patients were overweight(54.8%).Theε4 allele was associated with SC(OR=0.55,95%CI:0.31-0.98,P=0.042)and mild fibrosis(F1-F2)in CHC patients(OR 0.091,95%CI 0.01-0.75,P=0.020).LDL-c≥101.5 mg/dL(OR=0.20,95%CI:0.10-0.41,P<0.001)and BMI≥26.6 kg/m2(OR=0.37,95%CI:0.18-0.76,P<0.001)were associated with SC status;while ALT≥50.5 IU/L was negatively associated(OR=5.67,95%CI:2.69-11.97,P<0.001).CONCLUSION In SC patients,the APOEε4 allele and LDL-c conferred a protective effect in the course of the HCV infection in the context of excess body weight.展开更多
Statins have been shown to be effective in reducing cardiovascular events.Their magnitude of benefits has been proportionate to the reduction in low-density lipoprotein cholesterol(LDL-c).Intensive lipid-lowering ther...Statins have been shown to be effective in reducing cardiovascular events.Their magnitude of benefits has been proportionate to the reduction in low-density lipoprotein cholesterol(LDL-c).Intensive lipid-lowering therapies using ezetimibe and more recently proprotein convertase subtilisin kexin 9 inhibitors have further improved clinical outcomes.Unselective application of these treatments is undesirable and unaffordable and,therefore,has been guided by LDL-c level.Nonetheless,the residual risk in the post-statin era is markedly heterogeneous,including thrombosis and inflammation risks.Moreover,the lipoprotein related risk is increasingly recognised to be related to other non-LDL-c markers such as Lp(a).Emerging data show that intensive lipid-lowering therapy produce larger absolute risk reduction in patients with polyvascular disease,post coronary artery bypass graft and diabetes.Notably,these clinical entities share similar phenotype of large burden of atherosclerotic plaques.Novel plaque imaging may aid decision making by identifying patients with propensity to develop lipid rich plagues at multi-vascular sites.Those patients may be suitable candidates for intensive lipid lowering treatment.展开更多
Background Hypercholesterolemia is a major risk factor for cardiovascular events in patients with established atherosclerotic disease (EAD) and in those with multiple risk factors (MRFs). This study aimed to investiga...Background Hypercholesterolemia is a major risk factor for cardiovascular events in patients with established atherosclerotic disease (EAD) and in those with multiple risk factors (MRFs). This study aimed to investigate the rate of optimal low-density lipoprotein (LDL) cholesterol level in a multicenter registry of patients at high risk for cardiovascular events. Methods A multicenter registry of EAD and MRF patients was conducted. Demographic data,medical history,cardiovascular risk factors,anthropometric data,laboratory data,and medications were recorded and analyzed. We classified patients according to target LDL levels based on recommendation by the European Society of Cardiology (ESC) 2011 into Group 1 which is EAD and diabetes or chronic kidney disease (CKD)–target LDL below 70 mg/dL,and Group 2 which is MRF without diabetes or CKD–target LDL below 100 mg/dL. The rate of optimal LDL level in patients with Group 1 and Group 2 was analyzed and stratified according to the treatment pattern of lipid-lowering medications. Results A total of 3100 patients were included. Of those,51.7% were male. Average age was 65.8 ± 9.7 years. Average LDL level was 96.3 ± 32.6 mg/dL. A vast majority (92.7%) received statin and 9.3% received ezetimibe. Optimal LDL level was achieved in 20.3% of patients in Group 1 (LDL < 70 mg/dL),and in 46.6% in Group 2 (LDL < 100 mg/dL). The overall rate of optimal LDL control was 23% since 89.6% of study population belongs to Group 1. The rate of optimal LDL was not different between high and low potency statin. Factors that were associated with optimal LDL control were older age,the presence of coronary artery disease or peripheral artery disease. Conclusions The rates of optimal LDL level were unacceptably low in this study population. As such,a strategy to improve LDL control in high-risk population should be implemented.展开更多
The American Diabetes Association (ADA) 2013 guidelines state that a reasonable hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a hemoglobin A1c level of less than 6.5% may be considere...The American Diabetes Association (ADA) 2013 guidelines state that a reasonable hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a hemoglobin A1c level of less than 6.5% may be considered in adults with short duration of diabetes, long life expectancy, and no significant cardiovascular disease if this can be achieved without significant hypoglycemia or other adverse effects of treatment. A hemoglobin A1c level less than 8.0% may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced macrovascular and microvascular complications, extensive comorbidities, and long-standing diabetes in whom the hemoglobin A1c goal is difficult to attain despite multiple glucoselowering drugs including insulin. The ADA 2013 guidelines recommend that the systolic blood pressure in most diabetics with hypertension should be reduced to less than 140 mmHg. These guidelines also recommend use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in the treatment of hypertension in diabetics unless they are pregnant. Diabetics at high risk for cardiovascular events should have theirserum low-density lipoprotein (LDL) cholesterol lowered to less than 70 mg/dL with statins. Lower-risk diabetics should have their serum LDL cholesterol reduced to less than 100 mg/dL. Combination therapy of a statin with either a fibrate or niacin has not been shown to provide additional cardiovascular benefit above statin therapy alone and is not recommended. Hypertriglyceridemia should be treated with dietary and lifestyle changes. Severe hypertriglyceridemia should be treated with drug therapy to reduce the risk of acute pancreatitis.展开更多
Objective Foreign studies have reported that coronary artery disease(CAD) patients with high baseline low-density lipoprotein cholesterol(LDL-C) may have a good prognosis, which is called the “cholesterol paradox”. ...Objective Foreign studies have reported that coronary artery disease(CAD) patients with high baseline low-density lipoprotein cholesterol(LDL-C) may have a good prognosis, which is called the “cholesterol paradox”. This study aimed to examine whether the “cholesterol paradox” also exists in the Chinese population.Methods A total of 2,056 patients who underwent the first percutaneous coronary intervention(PCI)between 2014 and 2016 were enrolled in this retrospective cohort study and classified into two groups based on baseline LDL-C = 2.6 mmol/L(100 mg/d L). The outcomes of interest included major adverse cardiovascular events(MACE), all-cause mortality, recurrent nonfatal myocardial infarction, unexpected coronary revascularization, or any nonfatal stroke.Results All-cause mortality occurred in 8 patients(0.7%) from the low-LDL-C group and 12 patients(2.4%) in the high-LDL-C group, with a significant difference between the two groups(adjusted hazard ratio: 4.030, 95% confidence interval: 1.088–14.934;P = 0.037). However, no significant differences existed for the risk of MACE or other secondary endpoints, such as unexpected revascularization, nor any nonfatal stroke in the two groups.Conclusion In this study, a high baseline LDL-C was not associated with a low risk of clinical outcomes in CAD patients undergoing first PCI, which suggested that the “cholesterol paradox” may be inapplicable to Chinese populations.展开更多
Objective There is a large population of patients classified as complex higher-risk and indicated patients(CHIPs)in China with a poor prognosis.The treatment of these patients is complex and challenging,especially whe...Objective There is a large population of patients classified as complex higher-risk and indicated patients(CHIPs)in China with a poor prognosis.The treatment of these patients is complex and challenging,especially when acute cardiac events occur,such as acute coronary syndrome(ACS)or heart failure.Pharmacotherapy and some mechanical circulatory support(MCS)therapeutic devices can provide stable hemodynamic support for CHIPs-percutaneous coronary intervention(PCI).LDL-C is an important pathogenic factor in atherosclerosis,and the target of blood lipid control.Recent studies have revealed that lipoprotein(a)[Lp(a)],which is formed when a covalent bond between apolipoprotein(a)and apolipoprotein B-100 is made,produces an LDL-like particle.This particle is an independent risk factor for the development of atherosclerosis,and is closely correlated to stent thrombosis and restenosis.Furthermore,this requires active intervention.PCSK9 inhibitors have been used in lipid-lowering treatment,and preventing atherosclerosis.The present study explores the efficacy of PCSK9 inhibitors in CHIPs-ACS,and the association between the change in Lp(a)and survival after 2 years of follow-up.Methods The present real-world,prospective control study enrolled 321 CHIPs-ACS who underwent emergency PCI from August 2019 to November 2020,and these patients were followed up for 2 years.These patients were divided into two groups:PCSK9 group(n=161)given the combined PCSK9 inhibitor(140 mg of evolocumab every 2 weeks)and statins-based therapy,and SOC group(n=160)treated with statin-based lipid-lowering therapy alone.Then,the change in lipid index was measured,and the cardiovascular(CV)event recurrence rate was evaluated after one month and 2 years.Afterwards,the contribution of serum lipid parameters,especially the Lp(a)alteration,in patients with earlier initiation of the PCSK9 inhibitor to the CV outcome was analyzed.Results The LDL-C level was significantly reduced in both groups:52.3%in the PCSK9 group and 32.3%(P<0.001)in the SOC group.It is noteworthy that the Lp(a)level decreased by 13.2%in the PCSK9 group,but increased by 30.3%in the SOC group(P<0.001).Furthermore,the number of CV events was not significantly different between the PCSK9 and SOC groups after the 2-year follow-up period.In the PCSK9 group,the Lp(a)reduction was associated with the baseline Lp(a)levels of the patients(r2=−0.315,P<0.001).Moreover,the decrease in Lp(a)contributed to the decline in CV events in patients who received ACS CHIPs-PCI,and the decrease in Lp(a)level was independent of the LDL-C level reduction.Conclusion The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a)levels in ACS CHIPs-PCI.However,further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.展开更多
Low-density lipoprotein(LDL)is the main carrier of cholesterol and cholesteryl ester in circulation.High plasma levels of LDL cholesterol(LDL-C)are a major risk factor of atherosclerotic cardiovascular disease(ASCVD)....Low-density lipoprotein(LDL)is the main carrier of cholesterol and cholesteryl ester in circulation.High plasma levels of LDL cholesterol(LDL-C)are a major risk factor of atherosclerotic cardiovascular disease(ASCVD).LDL-C lowering is recommended by many guidelines for the prevention and treatment of ASCVD.Statins,ezetimibe,and proprotein convertase subtilisin/kexin type 9 inhibitors are the mainstay of LDL-C-lowering therapy.Novel therapies are also emerging for patients who are intolerant to statins or respond poorly to standard treatments.Here,we review the most recent advances on LDL-C-lowering drugs,focusing on the mechanisms by which they act to reduce LDL-C levels.The article starts with the cornerstone therapies applicable to most patients at risk for ASCVD.Special treatments for those with little or no LDL receptor function then follow.The inhibitors of ATP-citrate lyase and cholesteryl ester transfer protein,which are recently approved and still under investigation for LDL-C lowering,respectively,are also included.Strategies targeting the stability of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cholesterol catabolism can be novel regimens to reduce LDL-C levels and cardiovascular risk.展开更多
Objective: To seek a new biochemical index for diagnosis of coronary heart disease (CHD)of shen-Yang deficiency syndrom (CHD-SYD). Methods: Sixty-one patients with CHD were divided into 3 groups according to their TCM...Objective: To seek a new biochemical index for diagnosis of coronary heart disease (CHD)of shen-Yang deficiency syndrom (CHD-SYD). Methods: Sixty-one patients with CHD were divided into 3 groups according to their TCM Syndrome type, 10 patients in the group without Xin-Qi deficiency (Group A), 25 in the group with Xin-Qi deficiency but without Shen-Yang deficiency (Group B) and 26 in the group both with Xin-Qi deficiency and Shen-Yang deficiency (Group C). Levels of 17-hydroxy-corticosteroid in urine (urinary 17-OHCS) per 24 hrs, and serum level of high density lipoprotein cholesterol (HDL-C) and high density lipoprotein phospholipid (HDL-PL) in them were determined in synchrostep and compared with those in the control group of 23 healthy aged persons. urinary 17-OHCS per 24 hrs was taken as the diagnostic standard to screen a new index for diagnosis of Shen-Yang deficiency Syndrome, and preliminary appraisal to the index was made. Results: Serum HDL-PL in the CHD-SYD patients( Group C) was 616±157 mg/L, which was obviously lower than that in the patients of Group A and B. With low HDL-PL (<650 mg/L) used as the index to diagnose CHD-SYD, the sensitivity was 73%, the specificity 86% and the accuracy 80%. Conclusion: HDL-PL <650 mg/L could be adopted as an index for CHD-SYD diagnosis, which is simple and practical.展开更多
Serum lipids were determined in 100 psoriatics and the results indicated (1) the incidences of hypercholesterolemia (9%) and hypertriglyceridemia (17%) in psoriatics were significantly higher than in controls; (2) the...Serum lipids were determined in 100 psoriatics and the results indicated (1) the incidences of hypercholesterolemia (9%) and hypertriglyceridemia (17%) in psoriatics were significantly higher than in controls; (2) the mean values of serum TC, LDL-C and TC/HDL-C in psoriatics were significantly higher as compared with normal healthy controls matched for sex and age; (3) serum TC, LDL-C and TG values were significantly higher in cases whose disease was progressive or whose lesions involved more than 20% of body surface area than in cases whose disease stationary or lesions less than 20%. As the incidences of hypertension and coronary heart disease were also significantly higher in psoriatics than in controls, the authors proposed that some integrated relationship would exist.展开更多
目的探讨甘精胰岛素联合利拉鲁肽治疗2型糖尿病(T2DM)的效果及安全性。方法回顾性分析2019年10月-2021年2月收治的T2DM 80例,根据治疗方案分为观察组和对照组,每组40例。对照组予以甘精胰岛素治疗,观察组予以甘精胰岛素联合利拉鲁肽治...目的探讨甘精胰岛素联合利拉鲁肽治疗2型糖尿病(T2DM)的效果及安全性。方法回顾性分析2019年10月-2021年2月收治的T2DM 80例,根据治疗方案分为观察组和对照组,每组40例。对照组予以甘精胰岛素治疗,观察组予以甘精胰岛素联合利拉鲁肽治疗。比较2组治疗前后血糖相关指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c)]、血脂[低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)]水平、胰岛功能[胰岛素抵抗指数(HOMA-IR)和胰岛β细胞功能指数(HOMA-β)]、炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、淀粉样蛋白A(SAA)]、外周血磷脂酰肌醇激酶(PI3K)/蛋白激酶B(Akt)信号通路相关蛋白表达水平,统计2组不良反应发生情况。结果治疗8、16周后,观察组HOMA-β高于对照组,HOMA-IR、FPG、2 h PG、HbA1c、TG、LDL-C、TC水平低于对照组(P<0.05,P<0.01)。治疗8、16周后,观察组IL-6、SAA、TNF-α、PI3K、Akt低于对照组(P<0.05,P<0.01)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论甘精胰岛素联合利拉鲁肽治疗T2DM具有一定安全性,有助于改善患者胰岛功能,调控血糖、血脂水平,其机制可能与微炎症状态及外周血PI3K/Akt信号通路改善有关。展开更多
目的 探究住院老年2型糖尿病(type 2 diabetes mellitus,T2DM)患者合并肌少症的影响因素。方法 采用病例对照研究,回顾性分析2020年1月至2023年5月在北京医院内分泌科住院的老年T2DM患者,根据亚洲肌少症工作组(Asian Working Group for ...目的 探究住院老年2型糖尿病(type 2 diabetes mellitus,T2DM)患者合并肌少症的影响因素。方法 采用病例对照研究,回顾性分析2020年1月至2023年5月在北京医院内分泌科住院的老年T2DM患者,根据亚洲肌少症工作组(Asian Working Group for Sarcopenia,AWGS)2019年诊断标准诊断肌少症,应用多因素Logistic回归分析探究糖尿病合并肌少症的影响因素。结果 住院老年T2DM患者共469例,男性发生率高于女性(65.3%比34.7%,P<0.05)。糖尿病合并肌少症组(T2DM+Sar组)年龄高于T2DM无肌少症组(T2DM组)(P<0.01)。T2DM+Sar组49例,T2DM组420例。倾向性评分匹配(propensity score matching,PSM)后纳入糖尿病无肌少症组153例(T2DM组),T2DM+Sar组45例,矫正性别、年龄混杂因素后,T2DM+Sar组体质指数(body mass index,BMI)显著低于T2DM组(P <0.01),T2DM+Sar组中,BMI<24kg/m2患者比例更高(53.6%比11.1%,P<0.01),合并脑血管病及糖尿病周围神经病变比例更高(P<0.05)。T2DM+Sar组较T2DM组,Morse跌倒评分更高,日常生活能力(activities of daily living,ADL)评分更低,5次坐站所需时间更长、优势手握力低(均P<0.05),T2DM+Sar组的优势侧上肢臂围更细,总瘦组织含量、骨矿物质含量、内脏脂肪面积均低于T2DM组(P<0.05)。多因素Logistic回归分析显示:合并糖尿病周围神经病变(OR=3.348,95%CI:1.252~8.955)、内脏脂肪面积(OR=1.042,95%CI:1.005~1.079)、血尿酸(OR=1.007,95%CI:1.002~1.012)是老年T2DM合并肌少症的危险因素,BMI (OR=0.512,95%CI:0.363~0.721)、骨矿物质含量(OR=0.037,95%CI:0.008~0.186)是老年T2DM合并肌少症的保护因素。在BMI<24kg/m2的老年T2DM患者群体中,血尿酸(OR=1.010,95%CI:1.003~1.017)为老年T2DM合并肌少症的危险因素,下肢平均腿围(OR=0.624,95%CI:0.447~0.870)、高密度脂蛋白胆固醇(OR=0.195,95%CI:0.040~0.945)、总瘦组织含量(OR=0.889,95%CI:0.797~0.990)为老年T2DM合并肌少症的保护因素。结论 在老年T2DM的管理中,不建议将BMI控制在过低水平,身体成分对于老年T2DM患者合并肌少症的预测作用可能比BMI更有意义。展开更多
Background:Intensive systolic blood pressure(SBP)control improved outcomes in the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients(STEP)trial.Whether baseline serum lipid parameters influen...Background:Intensive systolic blood pressure(SBP)control improved outcomes in the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients(STEP)trial.Whether baseline serum lipid parameters influence the benefits of intensive SBP control is unclear.Methods:The STEP trial was a randomized controlled trial that compared the effects of intensive(SBP target of 110 to<130 mmHg)and standard(SBP target of 130 to<150 mmHg)SBP control in Chinese patients aged 60 to 80 years with hypertension.The primary outcome was a composite of cardiovascular disease events.A total of 8283 participants from the STEP study were included in this post hoc analysis to examine whether the effects of the SBP intervention differed by baseline low-density lipoprotein cholesterol(LDL-C)and non-high-density lipoprotein cholesterol(non-HDL-C)concentrations.Results:Regardless of the randomized SBP intervention,baseline LDL-C and non-HDL-C concentrations had a J-shaped association with the hazard of the primary outcome.However,the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline LDL-C level(P for interaction=0.80)and non-HDL-C level(P for interaction=0.95).Adjusted subgroup analysis using tertiles in LDL-C1(hazard ratio[HR],0.77;95%confidence interval[CI],0.52-1.13;P=0.18),LDL-C2(HR,0.81;95%CI,0.55-1.20;P=0.29),and LDL-C3(HR,0.68;95%CI,0.47-0.98;P=0.04)was provided,with an interaction P value of 0.49.Similar results were showed in non-HDL-C1(HR,0.87;95%CI,0.59-1.29;P=0.49),non-HDL-C2(HR,0.70;95%CI,0.48-1.04;P=0.08),and non-HDL-C3(HR,0.67;95%CI,0.47-0.95;P=0.03),with an interaction P-value of 0.47.Conclusion:High baseline serum LDL-C and non-HDL-C concentrations were associated with increased risk of primary cardiovascular disease outcome,but there was no evidence that the benefit of the intensive SBP control differed by baseline LDL-C and non-HDL-C concentrations.Clinical trial registration:ClinicalTrials.gov,NCT03015311.展开更多
基金Supported by Programa para el Desarrollo Profesional Docente(PRODEP)to Gonzalez-Aldaco K,No.UDG-PTC-1422Consejo Nacional de Ciencia y Tecnología(CONACYT)to Panduro A,No.2017-01-5254
文摘BACKGROUND Cholesterol is related to improvements in the rate of sustained virological response and a robust immune response against the hepatitis C virus(HCV).APOE gene polymorphisms regulate cholesterol levels modifying the course of the HCV infection.The relationship between cholesterol,APOE alleles,and the outcome of HCV infection has not been evaluated in the admixed population of Mexico.AIM To investigate the role of APOE-ε2,-ε3,and-ε4 alleles and the metabolic profile in the outcome of HCV infection.METHODS A total of 299 treatment-na?ve HCV patients were included in this retrospective study.Patients were stratified in chronic hepatitis C(CHC)(n=206)and spontaneous clearance(SC)(n=93).A clinical record was registered.Biochemical tests were assessed by dry chemistry assay.APOE genotypes were determined using a Real-Time polymerase chain reaction assay.RESULTS Total cholesterol,low-density lipoprotein cholesterol(LDL-c),triglycerides,and hypercholesterolemia were higher in SC than CHC patients as well as the frequency of the APOEε4 allele(12.4%vs 7.3%).SC patients were overweight(54.8%).Theε4 allele was associated with SC(OR=0.55,95%CI:0.31-0.98,P=0.042)and mild fibrosis(F1-F2)in CHC patients(OR 0.091,95%CI 0.01-0.75,P=0.020).LDL-c≥101.5 mg/dL(OR=0.20,95%CI:0.10-0.41,P<0.001)and BMI≥26.6 kg/m2(OR=0.37,95%CI:0.18-0.76,P<0.001)were associated with SC status;while ALT≥50.5 IU/L was negatively associated(OR=5.67,95%CI:2.69-11.97,P<0.001).CONCLUSION In SC patients,the APOEε4 allele and LDL-c conferred a protective effect in the course of the HCV infection in the context of excess body weight.
文摘Statins have been shown to be effective in reducing cardiovascular events.Their magnitude of benefits has been proportionate to the reduction in low-density lipoprotein cholesterol(LDL-c).Intensive lipid-lowering therapies using ezetimibe and more recently proprotein convertase subtilisin kexin 9 inhibitors have further improved clinical outcomes.Unselective application of these treatments is undesirable and unaffordable and,therefore,has been guided by LDL-c level.Nonetheless,the residual risk in the post-statin era is markedly heterogeneous,including thrombosis and inflammation risks.Moreover,the lipoprotein related risk is increasingly recognised to be related to other non-LDL-c markers such as Lp(a).Emerging data show that intensive lipid-lowering therapy produce larger absolute risk reduction in patients with polyvascular disease,post coronary artery bypass graft and diabetes.Notably,these clinical entities share similar phenotype of large burden of atherosclerotic plaques.Novel plaque imaging may aid decision making by identifying patients with propensity to develop lipid rich plagues at multi-vascular sites.Those patients may be suitable candidates for intensive lipid lowering treatment.
基金supported by the Heart Association of Thailand under the Royal Patronage of H.M. the Kingthe National Research Council of Thailand
文摘Background Hypercholesterolemia is a major risk factor for cardiovascular events in patients with established atherosclerotic disease (EAD) and in those with multiple risk factors (MRFs). This study aimed to investigate the rate of optimal low-density lipoprotein (LDL) cholesterol level in a multicenter registry of patients at high risk for cardiovascular events. Methods A multicenter registry of EAD and MRF patients was conducted. Demographic data,medical history,cardiovascular risk factors,anthropometric data,laboratory data,and medications were recorded and analyzed. We classified patients according to target LDL levels based on recommendation by the European Society of Cardiology (ESC) 2011 into Group 1 which is EAD and diabetes or chronic kidney disease (CKD)–target LDL below 70 mg/dL,and Group 2 which is MRF without diabetes or CKD–target LDL below 100 mg/dL. The rate of optimal LDL level in patients with Group 1 and Group 2 was analyzed and stratified according to the treatment pattern of lipid-lowering medications. Results A total of 3100 patients were included. Of those,51.7% were male. Average age was 65.8 ± 9.7 years. Average LDL level was 96.3 ± 32.6 mg/dL. A vast majority (92.7%) received statin and 9.3% received ezetimibe. Optimal LDL level was achieved in 20.3% of patients in Group 1 (LDL < 70 mg/dL),and in 46.6% in Group 2 (LDL < 100 mg/dL). The overall rate of optimal LDL control was 23% since 89.6% of study population belongs to Group 1. The rate of optimal LDL was not different between high and low potency statin. Factors that were associated with optimal LDL control were older age,the presence of coronary artery disease or peripheral artery disease. Conclusions The rates of optimal LDL level were unacceptably low in this study population. As such,a strategy to improve LDL control in high-risk population should be implemented.
文摘The American Diabetes Association (ADA) 2013 guidelines state that a reasonable hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a hemoglobin A1c level of less than 6.5% may be considered in adults with short duration of diabetes, long life expectancy, and no significant cardiovascular disease if this can be achieved without significant hypoglycemia or other adverse effects of treatment. A hemoglobin A1c level less than 8.0% may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced macrovascular and microvascular complications, extensive comorbidities, and long-standing diabetes in whom the hemoglobin A1c goal is difficult to attain despite multiple glucoselowering drugs including insulin. The ADA 2013 guidelines recommend that the systolic blood pressure in most diabetics with hypertension should be reduced to less than 140 mmHg. These guidelines also recommend use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in the treatment of hypertension in diabetics unless they are pregnant. Diabetics at high risk for cardiovascular events should have theirserum low-density lipoprotein (LDL) cholesterol lowered to less than 70 mg/dL with statins. Lower-risk diabetics should have their serum LDL cholesterol reduced to less than 100 mg/dL. Combination therapy of a statin with either a fibrate or niacin has not been shown to provide additional cardiovascular benefit above statin therapy alone and is not recommended. Hypertriglyceridemia should be treated with dietary and lifestyle changes. Severe hypertriglyceridemia should be treated with drug therapy to reduce the risk of acute pancreatitis.
基金supported by the Ethics Committee of Sir Run Run Shaw Hospital of Zhejiang University [NO.20200224-33]Key Project of Medical and Health Science and Technology of Zhejiang Province [NO. WKJ-ZJ-1715]+7 种基金Zhejiang Province Traditional Chinese Medicine Science and Technology Project [NO. 2017ZA006]Natural Science Foundation of Zhejiang Province [NO. LQ17H020006]Medical health Science and Technology project of Zhejiang Province [NO. 2017KY207]National Natural Science Foundation of China [82070408]Medical and health project [2021RC014]Hangzhou Medical Health Science and Technology Project [B20200116]“Pioneer” and “Leading Goose” R&D Program of Zhejiang[2023C04013]Administration of Traditional Chinese Medicine of Zhejiang Province [GZY-ZJ-KJ-23001]。
文摘Objective Foreign studies have reported that coronary artery disease(CAD) patients with high baseline low-density lipoprotein cholesterol(LDL-C) may have a good prognosis, which is called the “cholesterol paradox”. This study aimed to examine whether the “cholesterol paradox” also exists in the Chinese population.Methods A total of 2,056 patients who underwent the first percutaneous coronary intervention(PCI)between 2014 and 2016 were enrolled in this retrospective cohort study and classified into two groups based on baseline LDL-C = 2.6 mmol/L(100 mg/d L). The outcomes of interest included major adverse cardiovascular events(MACE), all-cause mortality, recurrent nonfatal myocardial infarction, unexpected coronary revascularization, or any nonfatal stroke.Results All-cause mortality occurred in 8 patients(0.7%) from the low-LDL-C group and 12 patients(2.4%) in the high-LDL-C group, with a significant difference between the two groups(adjusted hazard ratio: 4.030, 95% confidence interval: 1.088–14.934;P = 0.037). However, no significant differences existed for the risk of MACE or other secondary endpoints, such as unexpected revascularization, nor any nonfatal stroke in the two groups.Conclusion In this study, a high baseline LDL-C was not associated with a low risk of clinical outcomes in CAD patients undergoing first PCI, which suggested that the “cholesterol paradox” may be inapplicable to Chinese populations.
基金the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University(No.ZNLH-201907)the Hubei Province Health and Family Planning Scientific Research Project(No.WJ2019Q041)the Chinese Academy of Medical Science Innovation Fund for Medical Sciences(No.2021-I2M-1-009).
文摘Objective There is a large population of patients classified as complex higher-risk and indicated patients(CHIPs)in China with a poor prognosis.The treatment of these patients is complex and challenging,especially when acute cardiac events occur,such as acute coronary syndrome(ACS)or heart failure.Pharmacotherapy and some mechanical circulatory support(MCS)therapeutic devices can provide stable hemodynamic support for CHIPs-percutaneous coronary intervention(PCI).LDL-C is an important pathogenic factor in atherosclerosis,and the target of blood lipid control.Recent studies have revealed that lipoprotein(a)[Lp(a)],which is formed when a covalent bond between apolipoprotein(a)and apolipoprotein B-100 is made,produces an LDL-like particle.This particle is an independent risk factor for the development of atherosclerosis,and is closely correlated to stent thrombosis and restenosis.Furthermore,this requires active intervention.PCSK9 inhibitors have been used in lipid-lowering treatment,and preventing atherosclerosis.The present study explores the efficacy of PCSK9 inhibitors in CHIPs-ACS,and the association between the change in Lp(a)and survival after 2 years of follow-up.Methods The present real-world,prospective control study enrolled 321 CHIPs-ACS who underwent emergency PCI from August 2019 to November 2020,and these patients were followed up for 2 years.These patients were divided into two groups:PCSK9 group(n=161)given the combined PCSK9 inhibitor(140 mg of evolocumab every 2 weeks)and statins-based therapy,and SOC group(n=160)treated with statin-based lipid-lowering therapy alone.Then,the change in lipid index was measured,and the cardiovascular(CV)event recurrence rate was evaluated after one month and 2 years.Afterwards,the contribution of serum lipid parameters,especially the Lp(a)alteration,in patients with earlier initiation of the PCSK9 inhibitor to the CV outcome was analyzed.Results The LDL-C level was significantly reduced in both groups:52.3%in the PCSK9 group and 32.3%(P<0.001)in the SOC group.It is noteworthy that the Lp(a)level decreased by 13.2%in the PCSK9 group,but increased by 30.3%in the SOC group(P<0.001).Furthermore,the number of CV events was not significantly different between the PCSK9 and SOC groups after the 2-year follow-up period.In the PCSK9 group,the Lp(a)reduction was associated with the baseline Lp(a)levels of the patients(r2=−0.315,P<0.001).Moreover,the decrease in Lp(a)contributed to the decline in CV events in patients who received ACS CHIPs-PCI,and the decrease in Lp(a)level was independent of the LDL-C level reduction.Conclusion The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a)levels in ACS CHIPs-PCI.However,further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.
基金This work was supported by grants from the Ministry of Science and Technology(2018YFA0800703)the National Natural Science Foundation(91957103,31690102,32021003,and 91957208).B.-L.Song acknowledges the support from the Tencent Foundation through the XPLORER PRIZE.
文摘Low-density lipoprotein(LDL)is the main carrier of cholesterol and cholesteryl ester in circulation.High plasma levels of LDL cholesterol(LDL-C)are a major risk factor of atherosclerotic cardiovascular disease(ASCVD).LDL-C lowering is recommended by many guidelines for the prevention and treatment of ASCVD.Statins,ezetimibe,and proprotein convertase subtilisin/kexin type 9 inhibitors are the mainstay of LDL-C-lowering therapy.Novel therapies are also emerging for patients who are intolerant to statins or respond poorly to standard treatments.Here,we review the most recent advances on LDL-C-lowering drugs,focusing on the mechanisms by which they act to reduce LDL-C levels.The article starts with the cornerstone therapies applicable to most patients at risk for ASCVD.Special treatments for those with little or no LDL receptor function then follow.The inhibitors of ATP-citrate lyase and cholesteryl ester transfer protein,which are recently approved and still under investigation for LDL-C lowering,respectively,are also included.Strategies targeting the stability of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cholesterol catabolism can be novel regimens to reduce LDL-C levels and cardiovascular risk.
文摘Objective: To seek a new biochemical index for diagnosis of coronary heart disease (CHD)of shen-Yang deficiency syndrom (CHD-SYD). Methods: Sixty-one patients with CHD were divided into 3 groups according to their TCM Syndrome type, 10 patients in the group without Xin-Qi deficiency (Group A), 25 in the group with Xin-Qi deficiency but without Shen-Yang deficiency (Group B) and 26 in the group both with Xin-Qi deficiency and Shen-Yang deficiency (Group C). Levels of 17-hydroxy-corticosteroid in urine (urinary 17-OHCS) per 24 hrs, and serum level of high density lipoprotein cholesterol (HDL-C) and high density lipoprotein phospholipid (HDL-PL) in them were determined in synchrostep and compared with those in the control group of 23 healthy aged persons. urinary 17-OHCS per 24 hrs was taken as the diagnostic standard to screen a new index for diagnosis of Shen-Yang deficiency Syndrome, and preliminary appraisal to the index was made. Results: Serum HDL-PL in the CHD-SYD patients( Group C) was 616±157 mg/L, which was obviously lower than that in the patients of Group A and B. With low HDL-PL (<650 mg/L) used as the index to diagnose CHD-SYD, the sensitivity was 73%, the specificity 86% and the accuracy 80%. Conclusion: HDL-PL <650 mg/L could be adopted as an index for CHD-SYD diagnosis, which is simple and practical.
文摘Serum lipids were determined in 100 psoriatics and the results indicated (1) the incidences of hypercholesterolemia (9%) and hypertriglyceridemia (17%) in psoriatics were significantly higher than in controls; (2) the mean values of serum TC, LDL-C and TC/HDL-C in psoriatics were significantly higher as compared with normal healthy controls matched for sex and age; (3) serum TC, LDL-C and TG values were significantly higher in cases whose disease was progressive or whose lesions involved more than 20% of body surface area than in cases whose disease stationary or lesions less than 20%. As the incidences of hypertension and coronary heart disease were also significantly higher in psoriatics than in controls, the authors proposed that some integrated relationship would exist.
文摘目的探讨甘精胰岛素联合利拉鲁肽治疗2型糖尿病(T2DM)的效果及安全性。方法回顾性分析2019年10月-2021年2月收治的T2DM 80例,根据治疗方案分为观察组和对照组,每组40例。对照组予以甘精胰岛素治疗,观察组予以甘精胰岛素联合利拉鲁肽治疗。比较2组治疗前后血糖相关指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c)]、血脂[低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)]水平、胰岛功能[胰岛素抵抗指数(HOMA-IR)和胰岛β细胞功能指数(HOMA-β)]、炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、淀粉样蛋白A(SAA)]、外周血磷脂酰肌醇激酶(PI3K)/蛋白激酶B(Akt)信号通路相关蛋白表达水平,统计2组不良反应发生情况。结果治疗8、16周后,观察组HOMA-β高于对照组,HOMA-IR、FPG、2 h PG、HbA1c、TG、LDL-C、TC水平低于对照组(P<0.05,P<0.01)。治疗8、16周后,观察组IL-6、SAA、TNF-α、PI3K、Akt低于对照组(P<0.05,P<0.01)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论甘精胰岛素联合利拉鲁肽治疗T2DM具有一定安全性,有助于改善患者胰岛功能,调控血糖、血脂水平,其机制可能与微炎症状态及外周血PI3K/Akt信号通路改善有关。
文摘目的 探究住院老年2型糖尿病(type 2 diabetes mellitus,T2DM)患者合并肌少症的影响因素。方法 采用病例对照研究,回顾性分析2020年1月至2023年5月在北京医院内分泌科住院的老年T2DM患者,根据亚洲肌少症工作组(Asian Working Group for Sarcopenia,AWGS)2019年诊断标准诊断肌少症,应用多因素Logistic回归分析探究糖尿病合并肌少症的影响因素。结果 住院老年T2DM患者共469例,男性发生率高于女性(65.3%比34.7%,P<0.05)。糖尿病合并肌少症组(T2DM+Sar组)年龄高于T2DM无肌少症组(T2DM组)(P<0.01)。T2DM+Sar组49例,T2DM组420例。倾向性评分匹配(propensity score matching,PSM)后纳入糖尿病无肌少症组153例(T2DM组),T2DM+Sar组45例,矫正性别、年龄混杂因素后,T2DM+Sar组体质指数(body mass index,BMI)显著低于T2DM组(P <0.01),T2DM+Sar组中,BMI<24kg/m2患者比例更高(53.6%比11.1%,P<0.01),合并脑血管病及糖尿病周围神经病变比例更高(P<0.05)。T2DM+Sar组较T2DM组,Morse跌倒评分更高,日常生活能力(activities of daily living,ADL)评分更低,5次坐站所需时间更长、优势手握力低(均P<0.05),T2DM+Sar组的优势侧上肢臂围更细,总瘦组织含量、骨矿物质含量、内脏脂肪面积均低于T2DM组(P<0.05)。多因素Logistic回归分析显示:合并糖尿病周围神经病变(OR=3.348,95%CI:1.252~8.955)、内脏脂肪面积(OR=1.042,95%CI:1.005~1.079)、血尿酸(OR=1.007,95%CI:1.002~1.012)是老年T2DM合并肌少症的危险因素,BMI (OR=0.512,95%CI:0.363~0.721)、骨矿物质含量(OR=0.037,95%CI:0.008~0.186)是老年T2DM合并肌少症的保护因素。在BMI<24kg/m2的老年T2DM患者群体中,血尿酸(OR=1.010,95%CI:1.003~1.017)为老年T2DM合并肌少症的危险因素,下肢平均腿围(OR=0.624,95%CI:0.447~0.870)、高密度脂蛋白胆固醇(OR=0.195,95%CI:0.040~0.945)、总瘦组织含量(OR=0.889,95%CI:0.797~0.990)为老年T2DM合并肌少症的保护因素。结论 在老年T2DM的管理中,不建议将BMI控制在过低水平,身体成分对于老年T2DM患者合并肌少症的预测作用可能比BMI更有意义。
文摘Background:Intensive systolic blood pressure(SBP)control improved outcomes in the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients(STEP)trial.Whether baseline serum lipid parameters influence the benefits of intensive SBP control is unclear.Methods:The STEP trial was a randomized controlled trial that compared the effects of intensive(SBP target of 110 to<130 mmHg)and standard(SBP target of 130 to<150 mmHg)SBP control in Chinese patients aged 60 to 80 years with hypertension.The primary outcome was a composite of cardiovascular disease events.A total of 8283 participants from the STEP study were included in this post hoc analysis to examine whether the effects of the SBP intervention differed by baseline low-density lipoprotein cholesterol(LDL-C)and non-high-density lipoprotein cholesterol(non-HDL-C)concentrations.Results:Regardless of the randomized SBP intervention,baseline LDL-C and non-HDL-C concentrations had a J-shaped association with the hazard of the primary outcome.However,the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline LDL-C level(P for interaction=0.80)and non-HDL-C level(P for interaction=0.95).Adjusted subgroup analysis using tertiles in LDL-C1(hazard ratio[HR],0.77;95%confidence interval[CI],0.52-1.13;P=0.18),LDL-C2(HR,0.81;95%CI,0.55-1.20;P=0.29),and LDL-C3(HR,0.68;95%CI,0.47-0.98;P=0.04)was provided,with an interaction P value of 0.49.Similar results were showed in non-HDL-C1(HR,0.87;95%CI,0.59-1.29;P=0.49),non-HDL-C2(HR,0.70;95%CI,0.48-1.04;P=0.08),and non-HDL-C3(HR,0.67;95%CI,0.47-0.95;P=0.03),with an interaction P-value of 0.47.Conclusion:High baseline serum LDL-C and non-HDL-C concentrations were associated with increased risk of primary cardiovascular disease outcome,but there was no evidence that the benefit of the intensive SBP control differed by baseline LDL-C and non-HDL-C concentrations.Clinical trial registration:ClinicalTrials.gov,NCT03015311.